It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Get the latest news and real-time alerts from Lexicon Pharmaceuticals, Inc. (LXRX) stock at Seeking Alpha.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results